Announcements Trials
Browse Landscape

Status

Completed 8Recruiting 4Withdrawn 3Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 7Observational 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1

Interventions

Blood Specimen Collection 17Surveys and Questionnaires 14Psychiatric Rehabilitation 7Therapeutics 6Polymerase Chain Reaction 5Interviews as Topic 5Immunohistochemistry 5Gene Expression Profiling 5Biopsy 5Radiotherapy 4Magnetic Resonance Spectroscopy 4High-Energy Shock Waves 4Reverse Transcriptase Polymerase Chain Reaction 3Microarray Analysis 3Fluorodeoxyglucose F18 3Abiraterone Acetate 3Watchful Waiting 2Standard of Care 2Specimen Handling 2Prednisone 2Methods 2Leuprolide 2In Situ Hybridization, Fluorescence 2Hematologic Tests 2Glucose Tolerance Test 2Drug Therapy 2Comparative Genomic Hybridization 2Chemotherapy, Adjuvant 2Biopsy, Fine-Needle 2Bariatric Surgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Observational × Abiraterone Acetate × Clear all
NCT02608359 2025-02-03

A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

Johnson & Johnson Private Limited

Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01692483 2015-12-02

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Janssen Pharmaceutica

Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡